From genetic risk screening to drug discovery, omics innovation is improving how we collect, analyze, and use biological information.
Companies involved in the capture, sequencing, and analysis of biological data are transforming healthcare, from disease detection with AI to treatment via precision medicine.
The “omics” sector spans biological data across genomic, transcriptomic, proteomic, and metabolomic data. It includes companies like Karius, which aims to help clinicians detect diseases earlier, and Genome Medical, which helps patients better understand their specific genetic risks.
In recent years, new companies have emerged to leverage omics in every part of the patient journey. Stakeholders across the healthcare ecosystem are using these technologies to improve patient outcomes and bring down costs in the process.
FREE DOWNLOAD: THE COMPLETE DIGITAL HEALTH 150 LIST
The Covid-19 pandemic has further amplified the role of omics in the healthcare system, as rapid sequencing and personalized treatment have become paramount in the fight against the virus.
Using the CB Insights platform, we identified 110+ private omics companies and mapped them according to 8 categories within the space, from clinical decision support to molecular diagnostics.
This market map consists of private, active companies only and is not intended to be exhaustive of the space. Categories are not mutually exclusive, and companies are mapped according to primary use case.
Please click to enlarge.
Want the full post? Become a CB Insights customer.
If you’re already a customer, log in here.